Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Tycoon Group Holdings Limited ( (HK:3390) ).
Tycoon Group Holdings’ indirect wholly owned subsidiary Tycoon Global has renewed its role as distributor of DEEJ-branded products in Hong Kong by entering into a new 2026 Distribution Agreement with DEEJ International, effective from 1 January to 31 December 2026. As DEEJ International is a subsidiary of CR Pharmaceutical, a substantial shareholder of Tycoon Group, the arrangement constitutes a continuing connected transaction under Hong Kong listing rules; with the annual cap exceeding HK$3 million but relevant ratios remaining under 5%, the deal is subject to reporting, announcement and annual review requirements but exempt from circular and independent shareholders’ approval, allowing the group to maintain an important supply relationship while navigating related-party transaction safeguards.
The most recent analyst rating on (HK:3390) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Tycoon Group Holdings Limited stock, see the HK:3390 Stock Forecast page.
More about Tycoon Group Holdings Limited
Tycoon Group Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates through subsidiaries such as Tycoon Global and is engaged in the distribution of healthcare and pharmaceutical products in Hong Kong. The group leverages partnerships with major pharmaceutical players, including connected entities linked to substantial shareholders, to expand its product portfolio and distribution reach in the local market.
Average Trading Volume: 793,147
Technical Sentiment Signal: Sell
Current Market Cap: HK$277.1M
See more insights into 3390 stock on TipRanks’ Stock Analysis page.